OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Paul Edison

4 Projects | 1 Researchers | $5,798,540 Invested

2022

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP

Evaluating the safety and efficacy of PDE-5 inhibitor as a treatment for early stages of Alzheimer's disease

  • Funding Amount: $3,000,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuronal Degeneration
  • Status: Active

2021

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP

Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD)

  • Funding Amount: $2,000,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuronal Degeneration
  • Status: Active

2017

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP

Evaluating the effects of the novel GLP-I analogue, liraglutide, in patients with Alzheimer's disease (ELAD Study) - Open Label Extension

  • Funding Amount: $340,540
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2011

Imperial College London

Paul Edison, MD, MRCP, PhD, FRCPI, FRCP

Effect of Novel GLP1 analogue, Liraglutide on microglial activation and cerebral glucose metabolism in mild Alzheimer's disease.

  • Funding Amount: $458,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Closed